2026 International Online Conference on Tropical Medicine and Infectious Disease
Part of the International Online Conference on Tropical Medicine and Infectious Disease series
1–2 July 2026
15 March 2026
1 April 2026
26 June 2026
Vector-Borne Diseases, Parasitic Diseases, Zoonotic Diseases, Neglected Tropical Diseases, One Health, Antimicrobial Resistance, Travel Health, Public Health, Infectious Diseases
- Go to the Sessions
- Event Details
-
- Frequently Asked Questions (FAQ)
- Welcome from the Chair
- Program Overview
- CTMID 2026 Program (DAY 1)
- CTMID 2026 Program (DAY 2)
- Abstract Book
- Event Chair & Committee Members
- Event Speakers
- Sessions
- Registration
- Instructions for Authors
- Publication Opportunities
- Event Awards
- Sponsors and Partners
- Partner Conferences
- Conference Secretariat
- List of Accepted Submissions
- Events in series CTMID
Last Day for Free Registration! (26th June 2026)
Register for Free HERE.
Your abstract presentation type has been notified. Please check your email, including junk mail box, to avoid missing notifications. Thank you for your patience.
For any inquiries, please contact us at ctmid2026@mdpi.com.
Frequently Asked Questions (FAQ)
Q1. Is it still possible to submit an abstract for an oral or poster presentation at this time?
No, the abstract submission period closed on 15 March 2026.
Q2. I have been selected for an oral/poster presentation. When will it take place, and how can I join?
You can check the exact schedule on the conference program available on the official website. Within one week before the conference, you will receive multiple reminders with the login link and session details. Please make sure to check your email regularly.
Q3. My abstract was accepted as a poster presentation. How should the Poster Presentation be?
Poster presentations will be conducted CTMID 2026 conference websites, where the uploaded poster can be viewed in the "Poster Gallery" section, allowing registrants and viewers to participate and leave questions for further discussions.
Q4. I cannot find the option or link to upload my poster. When and how can I upload it?
Only the submitting author has access to the “upload” function on Sciforum. If you cannot upload your file, please send it along with your Sciforum ID to ctmid2026@mdpi.com.
Please upload your file to the Sciforum platform before the conference begins.
Q5. Will I receive a Certificate of Participation? How and when will the certificates be issued?
Yes. All participants at the event and attendees to the live session are entitled to a certificate after the conference. Certificates will be available for download in the My Certificates section on Sciforum after conference closing, and you will be notified by email once they are ready.
Q6. My abstract has been accepted, but I did not receive a notification for an oral or poster presentation. Can I still present my work?
Due to limited time slots, not all accepted abstracts can be included as oral or poster presentations, which are selected by the session chairs. However, all accepted abstracts are eligible to upload a poster via your author dashboard. All uploaded posters will be displayed in the Poster Gallery section on the conference website from the start of the event, where participants can view and comment during the conference.
Welcome from the Chair
Dear Colleagues and Participants,
It is with great pleasure that I welcome you to the 2026 International Online Conference on Tropical Medicine and Infectious Disease (CTMID 2026), which will be held online on 1–2 July 2026.
Organized By MDPI and the Tropical Medicine and Infectious Disease journal, this conference brings together leading researchers, public health professionals, clinicians, and policy-makers from around the world to share advances and challenges in the field of tropical medicine and infectious disease. Our virtual format ensures broad accessibility, allowing global participation without the need for travel.
CTMID 2026 provides a valuable platform to exchange cutting-edge knowledge and foster collaboration in tackling some of the world’s most pressing health issues. With sessions dedicated to Vector-Borne Diseases, One Health and Zoonotic Diseases, Neglected Tropical Diseases, and Antimicrobial Resistance, the conference reflects the urgent need for interdisciplinary approaches and global cooperation in combating infectious threats.
In addition to engaging presentations and live discussions, we are pleased to offer exciting publication opportunities. All accepted abstracts will be published in the conference report in Medical Sciences Forum. Outstanding contributions from each session will be eligible for conference awards. Moreover, instead of limiting presentations to a live poster session, all participants have the opportunity to upload and display their research in the form of a poster via the poster gallery on the conference website. Therefore, all participants with poster submissions for the poster gallery are now eligible for awards!
I encourage all participants to make the most of this opportunity to connect with peers, contribute to meaningful dialogue, and inspire future research directions.
On behalf of the organizing committee, thank you for your participation and support. I look forward to your valuable contributions and wish you a fruitful and impactful conference.
Kind regards,
Prof. Dr. John Frean
Event Chair
Pathologist, Parasitology Reference Lab, Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, University of the Witwatersrand, Johannesburg, South Africa
Program Overview
|
Day 1 |
Day 2 |
|
1 July 2026 - Morning |
2 July 2026 - Morning |
|
09:00 (CEST) |
09:00 (CEST) |
|
1 July 2026 - Afternoon |
2 July 2026 - Afternoon |
|
14:00 (CEST) |
14:00 (CEST) |
CTMID 2026 Program (DAY 1)
Program for DAY 1
Date: 1 July 2026 (Wednesday)
Morning Session
Time: 9:00 (CEST, Basel) | 03:00 (EST, New York) | 15:00 (CST Asia, Beijing)
Session 1: Vector - Borne Diseases
|
CEST |
Speaker |
Title |
| 09:00-09:10 |
Prof. Dr. John Frean |
Welcome from the Event Chair |
| 09:10-09:20 |
Prof. Dr. Basil Brooke |
Welcome from the Session Chair |
| 09:20-09:40 | Prof. Dr. Alfonso J. Rodríguez-Morales Invited Speaker |
To be announced. |
| 09:40-10:00 |
Prof. Dr. Toshio Hattori |
Understanding Resilience through Biomarkers in Disaster-Related and Tropical Infectious Diseases |
| 10:00-10:15 |
Prabir Kumar Sen |
Multisectoral Collaboration and Its Impact on Reducing Japanese Encephalitis (JE)/Acute Encephalitis Syndrome (AES) in India: An Integrated Approach to Global Health Security |
| 10:15-10:30 |
Ayesha Aswat |
Male Reproductive Transcript Silencing Reduces Fitness in Anopheles funestus |
|
10:30-10:45 |
Dr. Bhavya H P |
Molecular Characterization and Serotype Distribution of Dengue Virus in Bengaluru Rural |
|
10:45-11:00 |
Cintia Carolina Palavecino |
Spatial Coupling Between Aedes Aegypti Life Stages and Urban Land Surface Temperature in A Temperate Argentine City |
|
11:00-11:15 |
Marion Risse |
Identity, Not Sex or Menstrual Cycle, Drives Human Body Odor and Attractiveness to Anopheles Gambiae Mosquitoes |
|
11:15-11:30 |
Shune V. Oliver |
The Effect of Insecticide Exposure on The Gut Microbial Composition of Anopheles arabiensis (Diptera: Culicidae) from South Africa. |
|
11:30-14:00 |
BREAK |
|
Afternoon Session
Time: 14:00 (CEST, Basel) | 08:00 (EST, New York) | 20:00 (CST Asia, Beijing)
Session 3: Neglected Tropical Diseases
|
CEST |
Speaker |
Title |
|
14:00–14:10 |
Prof. Archie Clements |
Welcome from the Session Chair |
|
14:10-14:40 |
Prof. Dr. Russell Strothard |
The Changing Epidemiology of Schistosomiasis in Africa: Highlighting Hybrid, Zoonotic and Mixed Species Infections in Malawi |
|
14:40-15:00 |
Dr. Helen Mayfield |
Comparing Human and Vector-Based Indicators of Lymphatic Filariasis Transmission in Samoa |
|
15:00-15:20 |
Dr. Wendy Page Invited Speaker |
Strongyloidiasis - A Neglected, Preventable, Chronic Infectious Disease? |
|
15:20-15:40 |
Dr. Veerle Dermaux Msimang |
Human Schistosomiasis in South Africa: Laboratory-Based Prevalence, 2019-2024 |
|
15:40-15:55 |
Oladunni Nimota Adekunle |
Hidden in the Dirt: The Persistent Presence and Environmental Drivers of Soil-Transmitted Helminths in parts of Ogun State, Southwestern Nigeria |
|
15:55-16:10 |
Imrana Muhammad Arzika Selected Oral Speaker |
Prevalence of Urinary Schistosomiasis Among School-Age Children In Goronyo Local Government Area, Sokoto State, Nigeria |
|
16:10-16:25 |
Shivani Sharma Selected Oral Speaker |
Field Assessment of Lymphatic Filariasis, Transmission Dynamics, and Intervention Efficacy in Varanasi District (2019-2025). |
|
16:25-16:40 |
Elizabeth Oluwatoyin Ibikunle Selected Oral Speaker |
Prevelance and Intensity of Urogenital Schistosomiasis Among School Children in Spill Way Community of Ikere George Dam, Iseyin LGA,Oyo State, Nigeria. |
CTMID 2026 Program (DAY 2)
Program for DAY 2
Date: 2 July 2026 (Thursday)
Morning Session
Time: 9:00 (CEST, Basel) | 03:00 (EST, New York) | 15:00 (CST Asia, Beijing)
Session 2: One Health–Zoonotic Diseases
|
CEST |
Speaker |
Title |
|
09:00-09:10 |
Dr. Noore Alam |
Welcome from the Session Chair |
|
09:10-09:40 |
Prof. Cordia Chu |
One Health Action for Global Health Security |
|
09:40-10:00 |
Prof. Dr. Tjandra Yoga Aditama |
Zoonotic Diseases in Indonesia |
|
10:00-10:20 |
Dr. Gyanendra Gongal |
Hantavirus: What We Know and What We Do Not Know? |
|
10:20-10:35 |
Maksim Rakovich |
Climate-Driven Environmental Change and Zoonotic Spillover Risk: Implications for One Health Governance |
|
10:35-10:50 |
Md Rezaul Hasan |
Operationalising One Health for Dengue Prevention: Pathways Toward an Integrated Early Warning System in Bangladesh |
|
10:50-11:05 |
Onah Isegbe Emmanuel |
Parasitic Contamination of Soil Samples in Primary School Playgrounds in Jos North and South Local Government Areas, Plateau State |
|
11:05-11:20 |
Rakiiya Sikatarii Sarii |
Serological Evidence of Bat-Borne and Shrew-Borne Hantavirus Infections in Humans: A Comparative Study from Thailand, Sri Lanka, and Zambia |
|
11:20-11:35 |
Uttama Acharjee |
Broad-Spectrum Antiviral Activity of 3CLpro Inhibitors against Bat Coronaviruses Utilizing ACE2 or DPP4 Receptors |
|
11:35-11.50 |
Dr. Marco Antonio Natal Vigilato |
To be announced. |
|
11:50-14:00 |
BREAK |
Afternoon Session
Time: 14:00 (CEST, Basel) | 08:00 (EST, New York) | 20:00 (CST Asia, Beijing)
Session 4: Antimicrobial Resistance
|
CEST |
Speaker |
Title |
|
14:00–14:10 |
Dr. Constantinos Tsioutis & Dr. Josette Raymond |
Welcome from the Session Chair |
|
14:10-14:30 |
Dr. Tina Joshi |
Antimicrobial Resistance: From Microbial Evolution to Global Health Threat |
|
14:30-14:45 |
Suryanti Suryanti |
Digital Strategies to Improve Tuberculosis Case Notification in Private Healthcare Facilities: Implications for Antimicrobial Resistance Surveillance in Low- and Middle-Income Countries |
|
14:45-15:00 |
Aaftab G Pendari |
Longitudinal Impact of Antibiogram-Guided Antimicrobial Stewardship on Resistance Patterns and Multidrug-Resistant Organisms in a South Indian Tertiary Care Hospital |
|
15:00-15:15 |
Prince Kyere Dwaah |
Knowledge, Attitudes, and Practices Related to Antimicrobial Resistance Across the One Health Sector in Ghana: A Cross-Sectional Study |
|
15:15-15:30 |
Lotgarda Tayao Selected Oral Speaker |
Bridging the Diagnostic Gap: Evaluating the Concordance of Genotypic and Phenotypic AMR Detection in a Philippine Tropical Disease Center |
|
15:30-15:45 |
Jérôme Munyangi Wa Nkola Selected Oral Speaker |
Pilot Molecular Investigation of Artemisinin Resistance Markers in Artemisia annua Users for Malaria Treatment/Prevention: First African Follow-Up vs. ACT Controls in DRC |
|
15:45-16:00 |
Carlos Domínguez-Vargas Selected Oral Speaker |
Epidemiology of CTX-M Extended-Spectrum β-Lactamases in Escherichia coli Clinical Isolates in Mexico: A Systematic Review |
|
16:00-16:15 |
Oumar Abakar MAHAMED Selected Oral Speaker |
Prevalence and Determinants of Drug-Resistant Pulmonary Tuberculosis in the MENA Region: A Systematic Review and Meta-analysis |
Abstract Book
Event Chair
Pathologist, Parasitology Reference Lab, Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, University of the Witwatersrand, Johannesburg, South Africa
Associate Professor John Frean qualified in medicine and pathology at the University of the Witwatersrand, and has postgraduate qualifications from South African, British and Australian institutions. He is the founding Editor-in-Chief of the journal Tropical Medicine and Infectious Disease, which is the official journal of the Australasian College of Tropical Medicine. He is presently a postretirement advisor to the Centre for Emerging Zoonotic and Parasitic Diseases in the National Institute for Communicable Diseases (NICD, a division of the National Health Laboratory Service of South Africa) and also holds an appointment in the Wits Research Institute for Malaria, University of the Witwatersrand. Prof Frean’s interest is infectious diseases, particularly tropical, parasitic and zoonotic diseases. Postgraduate teaching responsibilities include Diploma in Tropical Medicine and Hygiene courses for Medicines Sans Frontieres and the universities of Sheffield, Glasgow and the Witwatersrand.
Session Chairs
Prof. Basil Brooke
Centre for Emerging Zoonotic & Parasitic Diseases, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, AND Wits Research Institute for Malaria, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
Associate Professor Basil Brooke is the head of the NICD’s Vector Control Reference Laboratory, Centre for Emerging Zoonotic & Parasitic Diseases, and is a member of the Wits Research Institute for Malaria (WRIM), University of the Witwatersrand. His collaborative research work over the past 25 years has primarily focused on identifying the entomological drivers of malaria transmission, especially insecticide resistance, and vector species assemblages and their corresponding behavioral/physiological traits. This work applies directly to the development of strategies designed to maintain effective malaria vector control in South Africa and the greater southern African region. He is also involved in the assessment of enhanced vector surveillance techniques, operational procedures for malaria outbreak response, new vector control products and alternative methods of control. Prof Brooke regularly consults with the World Health Organization (WHO) and United Nations Environment Program (UNEP) on technical issues relating to malaria vector control policy and practice, and serves on national and regional committees as part of the drive toward malaria elimination in southern Africa.
Dr. Noore Alam
Communicable Diseases Epidemiology, Public Health Intelligence Branch, Queensland Health, Brisbane, Australia
Noore Alam is an Advanced Epidemiologist at Queensland Health, Australia, with over 30 years of experience in public health, infectious disease epidemiology, and international health systems. He has worked with the Australian government and global organizations, including WHO, UNDP, WFP, and UNTAC, across Africa, South and South-East Asia, Central Asia, and Eastern Europe. In 2021-2023, Noore led the development of WHO’s Global Guidance on COVID-19 Contact Tracing and Quarantine, significantly shaping global response strategies for controlling the pandemic. He later served as Technical Officer and focal point for respiratory diseases of epidemic and pandemic potential at WHO EMRO in Cairo, overseeing 22 countries. His expertise spans emerging infectious diseases, One Health, pandemic preparedness, policy development, emergency management, and evaluation. He contributes to national and international advisory groups, including WHO’s Joint External Evaluations and Australia’s National Wastewater Surveillance Program. In 2016–17, he was a member of the Australian Health Ministers’ Advisory Council (AHMAC) Working Group on the Cost-effectiveness of Mandatory Folic Acid and Iodine Fortification National Policy. He also serves on the Editorial Board of Tropical Medicine and Infectious Disease, reflecting his commitment to advancing global health.
Prof. Archie Clements
School of Biological Sciences, Queen's University of Belfast, Belfast, UK
I joined Queen’s University Belfast in December 2023 as Pro-Vice-Chancellor (PVC) Research and Enterprise. As PVC, I am a member of the University Management Board, and am responsible for leading the development and implementation of the University’s research strategy. I chair the University Research and Innovation Committee and other decision-making bodies involved in research and enterprise. I am also the academic lead for implementation of the Belfast Region City Deal. Prior to joining Queen’s University Belfast, I held leadership roles at University of Plymouth, Curtin University in Western Australia and the Australian National University. I am an infectious disease epidemiologist and have studied the spatial epidemiology of parasitic, bacterial and viral diseases, predominantly in tropical regions of the world. I have also worked on community-based intervention studies exploring the role of multi-component, integrated strategies for sustainable infectious disease control. As of December 2023 I have co-authored over 300 peer-reviewed publications and been a chief investigator on competitively awarded research grants valued at over £18M.
Dr. Constantinos Tsioutis
School of Medicine, European University Cyprus, Nicosia, Cyprus
Medical Doctor trained in internal medicine, infection prevention and control, and healthcare management. He is Associate Professor at the European University Cyprus and leads the medical investigations clinic at Care Medical Institute, in Nicosia, Cyprus. Since 2021 he Chairs the Scientific Advisory Committee of the Cyprus Federation of Patient Associations (CyFPA-OSAK), the officially nationally recognized organization that represents more than 38 patient associations in Cyprus. He is also Scientific Coordinator of the European Committee on Infection Control (EUCIC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), member of the Expert Group for the WHO Global AMR Research Agenda in the human health sector, Scientific Advisor to the Greek Public Health Organization (EODY), and member of the Cyprus National Infection Control Committee. Between 2020 and 2023 he was Head of the Cyprus National COVID19 Scientific Advisory Committee. He is Associate Editor of several scientific journals and has published more than 85 peer-reviewed scientific papers including 3 international guidelines, with more than 4000 citations (h-index 31) in the field of infectious diseases and internal medicine.
Dr. Josette Raymond
University Paris cité, Paris, France
Josette Raymond, MD, PhD in Microbiology, is a distinguished professor at the University of Paris Descartes since 1985, specializing in bacterial pathogenesis, particularly Helicobacter pylori. She is a member of the Pasteur Institute and has contributed significantly to research on H. pylori's epidemiology, resistance, and diagnostics, including molecular characterization and transmission studies. Dr. Raymond has authored numerous peer-reviewed articles and served as an editor for scientific journals. She has mentored multiple PhD and MD students, and her work has influenced clinical practices in infection control. Her leadership includes participation in national health and microbiology committees, making her a leading expert in infectious diseases and microbiology.
Event Committee
College of Forestry, Wildlife & Environment, College of Veterinary Medicine, Auburn University, Auburn, USA
Centre for Emerging and Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases and Wits Research Institute for Malaria, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
Senior Public Health Officer, World Health Emergency Programme, WHO Regional Office for South-East Asia, New Delhi, India
Principal Medical Scientist, Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa
Senior Research Associate, Kirby Institute, University of New South Wales, Sydney, Australia
Director of Infectious Diseases and Institute's Clinical Lead Auditor, German Medical Institute, Limassol, Cyprus
Clinical Associate Professor of Infectious Diseases, European Cyprus University, Nicosia, Cyprus
Centre for Emerging Zoonotic & Parasitic Diseases, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, AND Wits Research Institute for Malaria, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa
HEAL Senior Research, Policy and Practice Fellow, Centre for Environment & Population Health, School of Medicine and Dentistry, Griffith University, Australia
Senior Operational Research Fellow, International Union Against Tuberculosis and Lung Disease, Paris, France
Team Lead for the Fleming Fund Country Grant to Indonesia, Jakarta, Indonesia
Wits Research Institute for Malaria, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Institute of Biology, College of Science, University of the Philippines Diliman, Quezon City, Philippines
Queensland Alliance for One Health Sciences, School of Veterinary Science, The University of Queensland, Gatton, Australia
veterinary public health; zoonotic diseases epidemiology; animal biosecurity; one health
Department of Medicine, Division of Infectious Diseases and Global Medicine, University of Florida College of Medicine, Gainesville, USA
chagas disease; Trypanosoma cruzi
National Institute of Health Dr. Ricardo Jorge, Porto, Portugal,
Institute for Research and Innovation in Health, University of Porto, Porto, Portugal
bladder cancer; infertility; schistosomiasis; neglected tropical diseases; estrogen metabolism; estrogen receptor signalling pathway
UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Brisbane, Australia
infectious diseases surveillance; integrated surveillance; Pacific islands; health systems; operational research; health policy research; public health
Public Health Program, Department of Behavioral and Applied Social Sciences, Marian University, Indianapolis, IN, USA
helminth infections; neglected tropical diseases; schistosomiasis; lymphatic filariasis; onchocerciasis, trachoma; implementation science; epidemiology
UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Brisbane, Australia
infectious diseases surveillance; operational research; Pacific islands; lymphatic filariasis; neglected tropical diseases
Laboratory of Infectious Disease Ecology in the Amazon, Oswaldo Cruz Foundation, Leônidas and Maria Deane Institute, Manaus, Brazil
helminths; filarial parasites; molecular eco-epidemiology; neglected disease vectors (NDVs)
Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
clinical gastroenterology; case management of malaria
Herbert Wertheim School of Public Health & Human Longevity Science, University of California, La Jolla, San Diego, USA
infectious disease epidemiology; community engagement; vaccine efficacy and effectiveness; arboviruses; dengue
Centre for Environment and Population Health, School of Medicine and Dentistry, Griffith University, Australia
Public health; Climate change impacts and adaptation; Health promotion
Environmental Health and WASH, International Centre for Diarrhoeal Disease Research, Bangladesh,
Heat and Health Research Centre, Faculty of Medicine and Health, University of Sydney, Australia
Climate Change; environmental pollution
Keynote Speakers
Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
The changing epidemiology of schistosomiasis in Africa: Highlighting hybrid, zoonotic and mixed species infections in Malawi
Based at the LSTM since 2011, I am a medical parasitologist with specific focus in epidemiology and control of neglected tropical diseases. My academic counsel is often sought internationally, I regularly provide expert scientific advice to the WHO-Geneva. Recently, I provided support in developing their 2022 Guideline on Control of Elimination of Schistosomiasis. With funding from the Wellcome Trust, UK my main research activity today is assessing the importance of hybridisation of schistosomes in both medical and veterinary settings in Malawi and Cameroon. In February 2025, I convened a two-day symposium with colleagues at the Royal Society in London to address the importance of hybrid schistosomes across Africa, and am lead editor of this meeting's proceedings soon to appear in Philosophical Transactions of the Royal Society, B. in January 2026.
Centre for Environment and Population Health, Griffith School of Environment, Griffith University, Australia
Climate change and HealthWorkplace Health Promotion and Safety ManagementHealth Promotion Theory and StrategiesSettings-based Integrated Planning for Environment and Population HealthResearch Design and PlanningReproductive HealthCommunity Development
Invited Speakers
Pan American Health Organization, Washington, D.C., USA
Marco Vigilato, DVM, is Regional Advisor on Zoonoses and Veterinary Public Health at the Pan American Health Organization/World Health Organization (PAHO/WHO) and Coordinator of the Zoonoses area at PAHO’s Pan American Center for Foot-and-Mouth Disease and Veterinary Public Health (PANAFTOSA). He has 25 years of professional experience, 15 of them with PAHO/WHO. His work focuses on regional technical cooperation, One Health governance, and strategies for the prevention, surveillance, and control of zoonoses across Latin America and the Caribbean. Priority areas include rabies elimination; neglected zoonoses such as echinococcosis; and envenoming caused by snakes, scorpions, spiders, and Lonomia, in collaboration with health and agriculture authorities and regional networks. He earned his veterinary degree from the University of Marília, completed a residency in Planning of Animal Health and Public Health, and holds a Master’s in Animal Health, Food Safety, and Veterinary Public Health from the São Paulo State University (UNESP). He is currently a PhD candidate at the Federal University of Rio de Janeiro (UFRJ) with a focus on One Health. Earlier roles include Head of the Center for Vector and Zoonoses Control (Birigui); work in animal health services at IAGRO (Mato Grosso do Sul); university lecturer and Veterinary Hospital Director; and managerial positions at the São Paulo Municipality Health Department (including Head of the Center for Zoonoses Control—CCZ, a PAHO/WHO Collaborating Centre). He has authored peer-reviewed articles and institutional technical publications on zoonoses, intersectoral collaboration, and One Health.
Centre for Emerging Zoonotic and Parasitic Diseases, National Institute for Communicable Diseases, Johannesburg, South Africa
Human schistosomiasis in South Africa: laboratory-based prevalence, 2019-2024
Dr. Veerle Msimang is a bioengineer (Gent University) with an MSc in Veterinary Epidemiology and Public Health from the University of London and a PhD in Veterinary Science from the University of Pretoria. Since 2012, she has served as an epidemiologist at the National Institute for Communicable Diseases – NHLS, within the Centre for Emerging Zoonotic and Parasitic Diseases. Rift Valley fever, arboviruses, viral hemorrhagic fevers, schistosomiasis, brucellosis, and leptospirosis are just a few of the emerging and neglected zoonotic diseases that she has surveilled and studied in her role. She supervises MSc/MPH students in the SA Field Epidemiology Program at the Universities of Pretoria and the Witwatersrand, works on research projects, has a good publication record consistent with her work on zoonotic diseases, and has an NRF C3 grade. She is a member of the South African One Health Forum, the Rabies Advisory Group, and technical working groups tasked with implementing integrated approaches to promote awareness, prevent, and control zoonotic diseases in South Africa.
School of Earth and Environmental Sciences, Faculty of Science, University of Queensland, Brisbane, Australia
Comparing Human and Vector-Based Indicators of Lymphatic Filariasis Transmission in Samoa
Dr Helen Mayfield is an interdisciplinary researcher whose work lies at the intersection of epidemiology, infectious diseases and environmental conservation. With a decade of experience studying zoonotic and vector-borne diseases, she employs advanced data modelling techniques like Bayesian networks and spatial models to explore the environmental drivers of disease. Helen holds a PhD in machine learning for environmental management. Her research focus is on refining and testing new disease surveillance methods and strategies, such as molecular xenomonitoring of mosquitoes, and targeted sampling to combat lymphatic filariasis in the Pacific islands.
Environment, Environmental Impact Assessment, Data Mining, Environment Protection, Social Network Analysis, Classical Statistics, Bayesian Network
Strongyloidiasis - a neglected, preventable, chronic infectious disease?
Dr Wendy Page, MBBS, FRACGP, FACRRM, MPHTM, FACTM and 2021 Northern Territory Australian of the Year, is a general practitioner who has worked in Aboriginal health for over three decades and with her colleagues in Strongyloides Australia, she shares the vision of a national strongyloidiasis control program to eliminate strongyloidiasis from endemically infected Indigenous communities by 2030. Strongyloidiasis, caused by the unique Strongyloides stercoralis, is a neglected, preventable, chronic infectious disease that can be life-threatening decades after the initial infection. Her doctoral research publications aim to raise awareness and address key misconceptions that hinder prevention and control programs. The primary healthcare strategy implemented at Miwatj Health Aboriginal Corporation integrated testing, treatment, and follow-up of chronic strongyloidiasis into the Indigenous preventive health assessment and the electronic health record system, reducing the prevalence from 44% to 10% across four endemic communities. Similar strategies, including One Health, are urgently required to meet the WHO NTD roadmap targets for 2021-2030. As guest editor of a special edition on Advances in Strongyloidiasis, with a special tribute to her mentor, friend, and colleague, the late Emeritus Professor Rick Speare, articles can be submitted before 31st July 2026.
strongyloidiasis; Strongyloides stercoralis; prevention; control; epidemiology; diagnosis; treatment; population health; primary healthcare
Antimicrobial Resistance: From Microbial Evolution to Global Health Threat
Dr Tina L. Joshi is Associate Professor A in Molecular Pathology at the University of Limerick, Ireland. She is an internationally recognised expert in antimicrobial resistance (AMR), infectious diseases and molecular diagnostics. Her interdisciplinary research focuses on antimicrobial and biocide resistance, infection prevention and control, and the development of rapid point-of-care diagnostics to tackle AMR. Dr Joshi is Editor-in-Chief of the Journal of Medical Microbiology and founded and co-chaired the Microbiology Society’s Knocking Out AMR (KOAMR) initiative from 2021–2024. She has contributed to international AMR advocacy and policy discussions, including the United Nations General Assembly High-Level Meeting on AMR (UNGA79).
antibiotic resistant pathogens; biocides; Diagnostics; clostridium difficile
Emeritus Professor, International Research Institute of Disaster Science, Tohoku University, Miyagi, Japan
Understanding Resilience through Biomarkers in Disaster-Related and Tropical Infectious Diseases
He is a medical doctor specializing in Internal Medicine. After graduating from Kyoto University Medical School and earning his PhD, he discovered that HTLV-1-infected leukemia cells (Adult T cell leukemia; ATL) are CD4 cells. He conducted research at the NIH in the USA, then moved to Kumamoto University, where he elucidated abnormalities in T cell receptor signaling and chemokine synthesis in ATL cells. Collaborating with Dr. Gallo’s group at NCI, he detected HIV infection in Japanese hemophiliacs. At the Institute for Virus Research, Kyoto University, he identified novel mechanisms of HIV infection. As a professor at Tohoku University, he advanced research on tropical infectious diseases, including HIV/TB, Dengue, leptospirosis, and Malaria. He demonstrated that matricellular proteins, such as osteopontin and galectin-9, are elevated and serve as biomarkers of disease severity. Following the Great East Japan Earthquake, he joined the International Research Institute of Disaster Science to focus on resilience in disaster-related infectious diseases. He served as Dean of the Human Security Course at Tohoku University and continued his research at Kibi International University. He is also Editor-in-Chief of Reports.
dengue, galectin-9, osteopontin, tuberculosis, hiv
Director, Graduate School, YARSI University, Jakarta
Zoonotic Diseases in Indonesia
Prof. Dr. Tjandra Yoga Aditama, MHA (Ind),DTM&H (UK), DTCE (Jpn), SpP(C)(Ind), FIRS (Ind), FIMMA (Ind) Present Position and Acivities - Director, Graduate School, YARSI University - Chair, Honorary Board, Indonesian Association of Pulmonologist - Advisory Board, Indonesian Anti Tuberculosis Society - Advisory Board, Stop TB Partnership Indonesia STPI) - Adjunct Professor, Griffith University Previous Position and Activities - Director General, Disease Control and Environmental Health, Ministry of Health, Indonesia (2009 - 2014) - Director General, National Institute of Health Research and Development (NIHRD), Ministry of Health, Indonesia (2014 - 2015) - Director Communicable Diseases (CDS), World Health Organization (WHO), South East Asia Regional Office (SEARO), 2018-2020 - Chair of Governing Board Meeting, SEAMEO (Southeast Asian Ministers of Education Organization), 2023 - Senior Disease Control Adviser and Technical Lead for G20 and ASEAN Support, Australia Indonesia Health Security Partnership (AIHSP), 2022 - 2023 - Member of Independent Allocation Vaccine Group (IAVG) – COVAX, 2020 – 2022 - Expert of Indonesian delegation on Intergovernmental Negotiating Body (INB) on Pandemic Agreement, 2024. - Expert of Indonesian delegation on Working Group on Amendments to the International Health Regulations -2005 (WGIHR), 2024 - Senior Project Leader, Airborne Infection Defence Platform (AIDP) Program in ASEAN, Stop TB Partnership Indonesia (STPI), 2023-2024
Infectious Diseases; Communicable Diseases; Global Health Security; Pandemic Preparedness; Emerging Diseases (e.g., Nipah Virus, Mpox, COVID-19); Tuberculosis (TB); Antimicrobial Resistance (AMR)
Faculty of Health Sciences, Universidad Cientifica del Sur, Lima, Peru
yellow fever; pregnancy; maternal health; arboviral diseases; vaccination; safety; effectiveness
Unite Head, Environmental Determinants, Climate Change, and One Health, WHO SEARO
Hantavirus: What we know and what we do not know?
Dr. Gyanendra Gongal is a Senior Public Health Officer, Head of Unit ‘Environmental Determinants, Climate Change and One Health’ under the Department of Health Promotion, Disease Prevention & Control (HDC) in the WHO Regional Office for South-East Asia (SEARO). Previously, he worked for the World Health Emergency Programme. He joined the World Health Organization in 2006. He received a Doctor of Veterinary Medicine and an honorary master’s in veterinary science from Moscow Veterinary Academy and an MSc in Epidemiology from the Free University of Berlin. He worked in various capacities under the Ministries of Health and Agriculture in Nepal for 17 years. He has actively participated in meetings and workshops related to zoonoses, food safety, One Health, and international health. He has been one of the founding members of the regional tripartite group (FAO-OIE-WHO) in the Asia-Pacific region to advocate for an operationalization of ‘One Health’ in tripartite platforms since 2010, which has helped to promote a better understanding of intersectoral collaboration for addressing rabies, emerging zoonoses, food safety, and aAMR at the human-animal interface. He has developed regional strategies, guidelines, and policy papers to prevent and control emerging infectious diseases, including zoonoses, and to enhance food safety. He was a Member of the One Health Network for the Global Governance of Infectious Diseases and Antimicrobial Resistance (Global 1HN) Advisory Committee in Canada. He is vice chair of the Global Leptospirosis Environmental Action Network (GLEAN) and a member of the WHO Ethical Review Committee. He received a Young Scientist Award from the Nepal Academy for Science and Technology in 1999 and the WHO Reward for Excellence in 2016. He has been a faculty member at several universities in Asia and America.
One Health; rabies; leptospirosis; food safety
AUSL–IRCCS di Reggio Emilia, Servizio di Prevenzione e Sicurezza Negli Ambienti di Lavoro (SPSAL), Local Health Unit of Reggio Emilia, Reggio Emilia, Italy
public health; vaccines; prevention; infectious diseases; prevention and protection at work; mass gathering and public health risks
Registration
The registration for CTMID 2026 will be free of charge! The registration includes attendance to all conference sessions.
If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.
Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 26 June 2026.
Instructions for Authors
The 2026 International Online Conference on Tropical Medicine and Infectious Disease (CTMID 2026) will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
2. Abstract Acceptance Notification: 1 April 2026 . You will be notified of the acceptance of an oral/poster presentation in a separate email.
Abstract submissions should be completed online by registering with www.sciforum.net and using the "Submit Abstract" function once logged into the system. No physical template is necessary.
1. The abstract structure should include the introduction, methods, results, and conclusions sections of about 250–300 words in length.
2. All accepted abstracts will be published in the conference report of the 2026 International Online Conference on Tropical Medicine and Infectious Disease (CTMID 2026) in MDPI’s Medical Sciences Forum journal (ISSN: 2673-9992); if you wish to publish an extended proceeding paper (4-8 pages), please submit it to the same journal after the conference.
3. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
4. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
5. All abstracts accepted for presentation will be collected in a book of abstracts, which will be published on the website after the conference.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session.
Authors are encouraged to prepare presentations using PowerPoint or equivalent software for online display alongside their abstract. If provided, slides will be presented directly on the conference website via the Sciforum.net slide viewer and should be prepared in the same format as a traditional conference presentation of research results. All slides must be converted to PDF format prior to submission to ensure accurate online display.
Each presentation should:
- Communicate the research question or objective, methodology, key results, and scientific novelty;
- Use a clear and logical structure, typically Introduction-Methods-Results&Discussion structure (IMRaD) or a field-appropriate alternative;
- Emphasize the relevance of the work;
- Support key findings with clear figures or tables where appropriate;
- Conclude with a critical interpretation of the results and their impact.
Posters should be designed to allow independent understanding of the research and clearly present the essential elements of the study.
Each poster should include:
- Title, authors, affiliations, and contact details (clearly displayed at the top);
- Brief introduction outlining the research objective;
- Concise methodology summary;
- Main results, supported by clear, well-labeled figures or tables where appropriate;
- Short conclusion summarizing key findings and their relevance.
Technical specifications:
Dimensions (cm): 84.1 × 118.9 (A0 - portrait)
Resolution:300 dpi
Pixel size (portrait, 300 dpi):9933 × 14043 px
Minimum font size:≥24
The poster template can be downloaded HERE. We will reach out to you closer to the dates of the conference with more information.
Note: The uploaded poster may be used as provided and serves as a reference. However, as long as the technical specifications are followed, scholars are welcome to use any poster template of their choice.
It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
1. Copyright Ownership
In accordance with Swiss copyright law, you, as the author, are the original creator of your work and retain full copyright ownership of your submitted abstract.
2. License Grant
By submitting your abstract for publication on the Sciforum.net platform, you grant MDPI, the platform’s publisher, a worldwide, royalty-free, non-exclusive license to:
- Publish, reproduce, and distribute the abstract online.
- Make the abstract publicly available in connection with the conference.
3. Author’s Retained Rights
This license is non-exclusive. As you retain full copyright, you are free to:
- Reuse, republish, and build upon your work in any way.
- Develop the abstract into a full paper for submission to other journals or publications.
- Enter into subsequent agreements, including granting an exclusive license or transferring copyright to another publisher for a future version of the work.
4. Author’s Responsibility
You remain solely responsible for complying with the policies of any other journal or publisher to which you may submit a subsequent version of your work, particularly concerning prior publication rules. MDPI and Sciforum.net bear no responsibility for any conflicts arising from your future submissions.
Any request concerning abstract or proceedings paper withdrawal should be communicated to the Conference Organizing Team as early as possible, preferably prior to final acceptance and confirmation of the conference program. Please note that once abstracts are published in the Conference Report or once Proceedings papers are published in the Proceedings journal and assigned a DOI, they become part of the permanent scholarly record and cannot be fully removed.
The responsible use of generative AI tools in the preparation of abstracts, posters, and presentations is permitted; however, any such use must be clearly disclosed, specifying the tool employed and its role. Authors retain full responsibility for the accuracy and integrity of their work.
Publication Opportunities
2. Proceeding Paper Publication
All accepted abstracts will be published in the report of the 2026 International Online Conference on Tropical Medicine and Infectious Disease (CTMID 2026) in the Medical Sciences Forum (ISSN: 2673-9992); authors of accepted abstracts are highly encouraged to submit an extended proceeding paper (ideally 4-8 pages in length) for free, please submit it to the same journal after the conference.
Please click HERE to submit your proceeding paper to the Medical Sciences Forum, and be sure to disclose the conference information in your cover letter or mention the conference name in your submission.
CTMID2026_proceeding_paper-template.dot
Publication Notice: Conference report and proceeding papers will undergo peer-review procedure. Acceptance at the conference does not ensure final publication.
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide 3 awards including Best Oral Presentation Awards, Best Poster Awards and Best Student Presentation Award.
The Awards
Number of Awards Available: 3
Eligibility: Open to all authors selected as oral speakers who have delivered their presentation. Failure to present, delegation of the presentation to another person, or use of AI-generated voice or similar substitutes will result in disqualification.
Criteria: Evaluation considers scientific rigor (clear, literature-supported research question or hypothesis, appropriate methodology, robust analysis and critical discussion of the results), IMRaD/field-appropriate structure, clarity of presented data (clear, well-labeled figures and tables), presentation skills and audience engagement, demonstrated scientific novelty and impact.
Prize: An award of CHF 300 and a certificate in recognition of your outstanding contribution.
2. Best Poster Award
Eligibility: Open to all authors who have presented their work through posters. Failure to present, delegation of the presentation to another person, or use of AI-generated voice or similar substitutes will result in disqualification.
Criteria: Evaluation considers scientific rigor (clear, literature-supported research question or hypothesis, appropriate methodology, robust analysis, and critical discussion of the results), IMRaD/field-appropriate structure enabling independent understanding, clarity of presented data (clear, well-labeled figures and tables), presentation skills (if orally presented), demonstrated scientific novelty and impact.
Prize: An award of CHF 200 and a certificate in recognition of your outstanding contribution.
Prize: An award of CHF 300 and a certificate in recognition of your outstanding contribution.
Winner Announcement: The award winners will be evaluated and selected by the scientific committee after the conference. Results will be announced on the website and all winners will be individually contacted via email.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
Partner Conferences

2026 ASTMH Annual Meeting
November 18-22, 2026 (Wednesday through Sunday)
Gaylord National Harbor
National Harbor, Maryland USA (adjacent to Washington, DC)
The ASTMH Annual Meeting is the premier international forum for the exchange of scientific and clinical advances in tropical medicine, hygiene and global health. World-class research findings, clinical updates and topical discussions about the hot-button global issues from the world’s brightest scientific experts and thought leaders are presented over five days.
More information is available at www.astmh.org
The American Society of Tropical Medicine and Hygiene, founded in 1903, is the largest international scientific organization of experts dedicated to reducing the worldwide burden of tropical infectious diseases and improving global health.
Conference Secretariat
Ms. Coco Hou
Mr. Zen Wang
Mr. Russell Wang
Email: ctmid2026@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
List of accepted submissions (81)
| Id | Title | Authors | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sciforum-174816 | Clinical and Epidemiological Profile of Human Brucellosis in Sétif, Algeria: A 4-Year Hospital-Based Study (2021–2024) |
,
FARIDA SAHLI
|
Show Abstract |
||||||||||||||||||||||||||||||||||||||
|
Introduction: Brucellosis remains a major public health concern in Algeria, particularly in agro-pastoral regions like Sétif. This study aims to describe the clinical, epidemiological, and microbiological characteristics of human brucellosis cases managed at the University Hospital of Sétif. Methods: A retrospective descriptive study was conducted on 37 patients hospitalized at the Infectious Diseases Department between 2021 and 2024. All cases were confirmed by the isolation of Brucella spp. from blood cultures or localized samples. Statistical analysis included 95% confidence intervals (CIs) for key proportions, Fisher’s exact test for categorical variables and the Binomial test for gender distribution. A p-value < 0.05 was considered statistically significant. Results: A total of 37 patients were included. A significant male predominance was confirmed (78.4% vs. 21.6%; p = 0.001), with a mean age of 43 years (SD ± 15.6). The temporal distribution showed a peak in 2022 (32.4%), followed by a fluctuation in annual incidence without a linear trend (p > 0.05). The hallmark clinical sign was undulant fever (97%), frequently associated with arthralgia (19%) and headache (11%). Focal osteoarticular complications were identified in 10.8% of the cohort (n=4), specifically spondylodiscitis (n=2) and sacroiliitis (n=2). Notably, all complicated cases occurred in male patients; however, this association did not reach statistical significance (Fisher’s exact test, p = 0.55), likely due to the limited sample size. Conclusion: Human brucellosis in Sétif is characterized by a high burden among middle-aged men and significant osteoarticular morbidity. The lack of a declining trend over four years underlines the urgency of an integrated "One Health" surveillance system to control the animal reservoir and improve early clinical detection. |
|||||||||||||||||||||||||||||||||||||||||
| sciforum-175674 | Spatial coupling between Aedes aegypti life stages and urban land surface temperature in a temperate Argentine city |
,
,
Julio Galarza ,
,
Maria López
|
Show Abstract |
||||||||||||||||||||||||||||||||||||||
|
Understanding how Aedes aegypti eggs and gravid female are spatially structured, and how they relate to urban temperature heterogeneity, is essential in improving vector surveillance. This study analyzed the spatial distribution patterns of egg and gravid female abundance of Ae. aegypti in the city of Reconquista (Argentina) during the 2024–2025 epidemiological season and assessed spatial associations between life stages and with land surface temperature (LST). Data obtained between December 2024 and March 2025 during montoring using ovitraps and gravid Aedes traps were analyzed. The mean abundance of eggs (EG) and gravid female (GF) (adjusted by active devices) was calculated. Spatial autocorrelation and the association between both stages were assessed using global univariate and bivariate Moran’s I statistics. Mean abundance was aggregated into a 600 m hexagonal grid, and bivariate LISA was used to identify local spatial clusters. Both EG and GF exhibited significant positive spatial autocorrelation, with clusters of high reproductive activity concentrated in specific sectors of the city. There was a significant positive global spatial association between EG abundance and GF female abundance. However, local LISA analysis showed that this association was spatially heterogeneous, with most areas not exhibiting significant local coupling. These results indicate that egg and gravid female distributions are spatially coupled at the urban scale, although this relationship is spatially heterogeneous and restricted to specific sectors of the city. We found a positive spatial association between EG and GF with LST, with nearly half of the study area exhibiting concordant High EG/GF–High LST or Low EG/GF–Low LST patterns. EG and GF abundance show clear spatial structuring across the evaluated life stages. Urban LST appears spatially coupled with EG and GF abundance, supporting a strong thermo-biological linkage in the urban landscape. |
|||||||||||||||||||||||||||||||||||||||||
| sciforum-174832 |
Clinical vulnerability patterns in human Cochliomyia hominivorax myiasis in Southern Mexico: an exploratory analytical study
, , , Dante Joel Márquez-González ,
Samantha Jonnue Ramírez-Flores ,
Miranda Citlali Pérez-Castellón ,
Gerardo Amaya-Tapia
Submitted: 09 Apr 2026 Abstract: Show Abstract |
,
,
,
Dante Joel Márquez-González ,
Samantha Jonnue Ramírez-Flores ,
Miranda Citlali Pérez-Castellón ,
Gerardo Amaya-Tapia
|
Show Abstract |
||||||||||||||||||||||||||||||||||||||
|
Introduction: Human myiasis caused by Cochliomyia hominivorax remains a neglected tropical zoonosis in Latin America despite regional eradication programs targeting the New World screwworm. Contemporary epidemiological and vulnerability patterns in Mexico are poorly characterized. We conducted an analytical exploratory study to describe clinical distribution and identify factors associated with complicated outcomes in confirmed human cases reported in Southern Mexico. Methods: A retrospective observational exploratory study was conducted, including 33 laboratory-confirmed human cases reported in the National Epidemiological Surveillance System (epidemiological week 29, 2025). Variables analyzed included age, sex, anatomical location, comorbidities, and clinical outcomes. Comorbidity was defined as documented chronic clinical conditions in the registry (e.g., diabetes mellitus, neoplasms, vascular disease, chronic kidney disease, malnutrition, alcohol use disorder). Age was summarized using the median and interquartile range (IQR). Proportions were calculated with 95% confidence intervals (95% CIs) using the Wilson method. Associations were assessed using Fisher’s exact test and crude odds ratios (ORs) with Haldane correction. Results: The median age was 60 years (IQR 48–74; range 17–87), and 63.6% were male (95% CI 46.6–77.8). Cephalic involvement was the most frequent presentation (45.5%; 95% CI 29.8–62.0). At least one comorbidity was present in 75.8% (95% CI 59.0–87.2), and ≥2 in 21.2%. Six patients (18.2%) had neoplastic disease, including skin cancer, basal cell carcinoma, lip cancer, tongue cancer, and parietal neoplastic lesions; all were located in the cephalic region (100%). Complicated outcomes occurred in 15.2% (95% CI 6.7–30.9), and case fatality was 3.0% (95% CI 0.5–15.3). One death occurred in a patient with multiple comorbidities; the specific cause of death was not publicly available. Conclusions: Human Cochliomyia hominivorax myiasis in Southern Mexico predominantly affects patients with comorbidities and conditions favoring tissue exposure. The observed association between cephalic neoplasms and infestation suggests that exposed tumor lesions may play a key role in pathogenesis. These findings provide clinical evidence of vulnerability factors in this neglected zoonosis. |
|||||||||||||||||||||||||||||||||||||||||
| sciforum-173416 |
"Effectiveness of Participatory Strategies for Prevention of Dengue and Leptospirosis: A Two-Year Controlled Community Trial in Santa Fe, Argentina"
, Renata Villarreal ,
Leda Beltramo ,
Mariano Leiva ,
Ludmila Bazan Dominguez ,
,
,
,
M. Andrea Previtali
Submitted: 18 Mar 2026 Abstract: Show Abstract |
,
Renata Villarreal ,
Leda Beltramo ,
Mariano Leiva ,
Ludmila Bazan Dominguez ,
,
,
,
M. Andrea Previtali
|
Show Abstract |
||||||||||||||||||||||||||||||||||||||
|
Introduction: The city of Santa Fe (Argentina) is highly exposed to environmental conditions that favor outbreaks of dengue and leptospirosis. Official public health campaigns often rely on top-down compliance-based approaches, underestimating the potential of community participation. This study aimed to quantify the effectiveness of participatory strategies compared to conventional methods through controlled community trials in four riverside neighborhoods with similar socio-environmental conditions. Methodology: In 2024/2025, two intervention sectors (Vuelta del Paraguayo / Manzana 2) and two control sectors (Colastiné / Boca) were established (n=80 households per site). The intervention involved training cycles for health promoters based on popular education and participatory action research (PAR), promoting community dialogue and territorial planning. Control areas received traditional, non-participatory campaigns. A longitudinal pre-post design was used. Indicators included: knowledge, attitudes, practices, and perceptions (KAPP); abundance of Aedes aegypti adults, larvae, and breeding sites; and rodent activity monitored through hair traps. Data were analyzed using generalized linear mixed models (GLMM) and logistic regressions to assess the interaction effect between treatment condition (participatory vs. control) and time in both trials. Results: Significant interaction effects were found (p < 0.05). The probability of finding potential larval breeding sites was reduced by 39% (OR: 0.61), larval breeding sites by 41% (OR: 0.59), and Ae. aegypti adults by 31% (OR: 0.69) compared to control groups (p < 0.05). Additionally, rodent activity was reduced by 44% (OR: 0.56). Furthermore, a significant increase in risk knowledge and perception was observed. Conclusion: Participatory methods demonstrate greater efficacy than traditional approaches in reducing biological risk indicators. Community empowerment acts as a cost-effective strategy by fostering social sustainability, reducing dependence on recurring chemical interventions, and mitigating the risk of zoonotic disease transmission in vulnerable settings |
|||||||||||||||||||||||||||||||||||||||||
| sciforum-175582 | Operationalising One Health for Dengue Prevention: Pathways Toward an Integrated Early Warning System in Bangladesh |
,
Paul Barnes ,
|
Show Abstract |
||||||||||||||||||||||||||||||||||||||
|
The epidemiology of dengue in Bangladesh is undergoing a fundamental shift, driven by climate variability, rapid urban expansion, and ecological change. Dengue is transforming a historically monsoon-bound disease into a persistent national health crisis. Recent outbreaks demonstrate expanding geographic distribution and altered transmission dynamics driven by rapid and unplanned urbanisation, and mosquito vector adaptation. These changes have reduced the effectiveness of conventional surveillance approaches that rely primarily on hospital-based reporting and reactive response. Addressing this evolving risk requires a predictive early warning system grounded in a One Health framework that integrates human, environmental, and vector surveillance. A retrospective analysis was conducted using national routine dengue surveillance datasets reported by the Directorate General of Health Services, Bangladesh, for 2024–2025, alongside system-level evidence, to evaluate readiness for a One Health-based Early Warning System (EWS). Data quality, reporting continuity, and operational feasibility were assessed using WHO data-quality assessment approaches. The datasets demonstrated nationwide reporting coverage but substantial data gaps, with approximately 53.2% of fields missing in 2024 and only 20.8% in 2025. Substantial data gaps, reporting inconsistencies, and limited interoperability constrain early outbreak detection. Current systems capture human clinical outcomes but lack systematic integration with entomological surveillance and ecological drivers such as temperature, rainfall, and humidity. These limitations reduce the ability to generate timely, actionable alerts. The evolving epidemiology of dengue in Bangladesh necessitates transitioning from conventional surveillance to a predictive One Health early-warning system. Implementing a One Health framework can operationalise multi-sectoral integration, strengthen data systems, and enable anticipatory public health action. Bangladesh represents a critical frontline example of how climate, ecological disruption, and human population dynamics are reshaping dengue transmission. This demands a transition from conventional surveillance toward integrated One Health early warning systems. A coordinated One Health EWS represents a critical pathway for improving climate-sensitive disease preparedness and reducing future dengue burden in Bangladesh. |
|||||||||||||||||||||||||||||||||||||||||
S1. Vector-Borne Diseases
Session Chair
Professor Basil Brooke, Centre for Emerging Zoonotic & Parasitic Diseases, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, AND Wits Research Institute for Malaria, School of Pathology, University of the Witwatersr
Show all published submissions (23) Hide published submissions (23)
Submissions
List of Papers (23) Toggle list
S2. One Health – Zoonotic Diseases
Session Chair
Dr. Noore Alam, Public Health Intelligence Branch, Queensland Public Health & Scientific Services (QPHaSS), Queensland Health, Brisbane, Australia
Show all published submissions (26) Hide published submissions (26)
Submissions
List of Papers (26) Toggle list
S3. Neglected Tropical Diseases
Session Chair
Professor Archie Clements, Pro-Vice-Chancellor Research & Enterprise, Queen’s University Belfast, United Kingdom
Show all published submissions (25) Hide published submissions (25)
Submissions
List of Papers (25) Toggle list
S4. Antimicrobial Resistance
Session Chairs
Dr. Constantinos Tsioutis, School of Medicine, European University Cyprus, Nicosia, Cyprus
Dr. Josette Raymond, University Paris cité, France



